SYGNIS AG / Key word(s): Capital Increase 02.10.2013 16:09 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ad hoc-Release according to § 15 WpHG SYGNIS AG plans rights offering Heidelberg, Germany, October 2, 2013 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03, Prime Standard) announced that the Management Board of SYGNIS today resolved with the approval of the Supervisory Board to increase the Company's share capital by up to EUR 1,170,532.00 from EUR 9,364,258.00 to up to EUR 10,534,790.00 by issuing up to 1,170,532 new shares against cash contribution. The Company plans to offer the new shares to its shareholders in a rights offering. The subscription ratio has been set at 8:1; i.e. eight existing shares entitle the shareholder to subscribe for one new share. The subscription price is EUR 2.65 per share. The offering will utilise existing authorised capital created by resolution at the Annual General Meeting on 28 August 2013. The New Shares carry full dividend rights as of 1 January 2013. New shares that are not subscribed in the course of the rights offering by existing shareholders will be offered to selected investors in a private placement at a purchase price equivalent to the subscription price. Shareholders may subscribe to the new shares during the subscription period, which is expected to begin on 8 October 2013 and end on 22 October 2013 at 12:00 noon CEST. There will be no organised trading in subscription rights. The new shares that can be subscribed in return for cash contributions are offered to shareholders by way of an indirect subscription right by Baader Bank Aktiengesellschaft, Unterschleissheim, Germany. Shareholders' subscription rights are determined based on their holdings of existing shares at the close of business of the day, 7 October 2013. SYGNIS plans to use the gross proceeds of approximately up to EUR 3.1 million to finance its operating business and further growth. For further details on the rights issue, please see the subscription offer provisionally planned to be published in the electronic Federal Gazette on 7 October 2013 and on the website of SYGNIS AG (www.sygnis.com). **** end of ad hoc **** For further information please contact: <pre> SYGNIS AG Pilar de la Huerta CEO/CFO Tel: +34-918063089 Email: pdelahuerta@sygnis.es </pre> About SYGNIS AG: www.sygnis.com After the merger in 2012 between X-Pol Biotech, specialising in DNA amplification and sequencing, and SYGNIS AG, listed in the German Stock Exchange (Prime Standard segment, Tick: LIO1; ISIN: DE000A1RFM03), SYGNIS' new mission is to develop and distribute technologies and products from X-Pol, which has a commercial product in the DNA amplification segment, QualiPhi(R) and is currently developing other products in the field of Next Generation Sequencing. . ### Disclaimer This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason.### 02.10.2013 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: SYGNIS AG Im Neuenheimer Feld 515 69120 Heidelberg Germany Phone: 06221 454-6 Fax: 06221 454-700 E-mail: contact@sygnis.de Internet: www.sygnis.de ISIN: DE000A1RFM03 WKN: A1RFM0 Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, München, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: SYGNIS AG: SYGNIS AG plans rights offering
Top 10 Most Recent News Articles
Duolingo Faces Lawsuit Over Alleged Investor Missteps
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue ReadingTop 5 Most Recently Viewed Articles
Crypto Developments: Circle's Blockchain, Ethereum Bets, and More
The Current Landscape of Cryptocurrency The last week in the world of cryptocurrency and finance has been nothing less than exhilarating. With significant developments, including the launch of a new blockchain by Circle Internet Group Inc. and major investments in Ethereum, there is plenty to discuss. Let’s explore the most noteworthy stories that are shaping the crypto...
Continue Reading
ezPaycheck 2025 Payroll Software: Cost-Effective Compliance Solution
ezPaycheck 2025: The Efficient Payroll Solution The new ezPaycheck 2025 payroll software is now available, offering businesses an excellent in-house solution for payroll processing that is both compliant and economical. This updated version comes with essential features designed to make payroll management easier than ever. Priced at just $169 for a single installation,...
Continue Reading
Investors of Applied Therapeutics, Inc. Should Take Action Now
Understanding the Securities Fraud Allegations Against Applied Therapeutics Applied Therapeutics, Inc. (APLT) has found itself at the heart of a securities fraud class action lawsuit. This legal proceeding has been announced by The Law Offices of Frank R. Cruz as they represent investors who acquired shares during a significant time frame. The legal challenge highlights...
Continue Reading
Ardagh Metal Packaging Reports Positive Year-End 2024 Results
Ardagh Metal Packaging's Year-End 2024 Results Ardagh Metal Packaging S.A. (NYSE: AMBP) recently reported their impressive results for the full year and fourth quarter of 2024. The company's performance is a reflection of strategic growth and resilience in a challenging market environment. Quarterly and Annual Performance Overview For the fourth quarter of 2024, Ardagh...
Continue Reading
Empowering Voices: The Call to Protect Our Children
Making a Stand Against Child Trafficking In a heartfelt initiative, ThinkCareBelieve has announced a powerful call to action aimed at ensuring the safety and protection of children across the nation. This initiative addresses the urgent concern of child trafficking and the plight of missing children, many of whom have been smuggled through borders and placed in unsafe...
Continue Reading